A healthcare-dedicated venture capital fund with offices in US and Europe is managed by a team of seasoned venture managers and entrepreneurs. The fund will make early-stage equity investments in preclinical and clinical-stage drug development companies. The investment size of the fund will range between USD 5-30 million per company. The fund prefers to invest in European-based companies, but exceptional opportunities in the US will also be considered. The fund has had its first closing and is actively seeking new investment opportunities.
The firm is seeking to invest in innovative drug development companies. The fund has a special interest in biologics and is open to all indications including orphan indications. Generics, reformulations or second-use products (“micro-innovation”) are not part of the investment strategy.
The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment